Distinguished in Heart Failure with Preserved Ejection Fraction (HFpEF)

Christian Hengstenberg

St. George's University Of London, 
London, ENG, GB 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Heart Failure with Preserved Ejection Fraction (HFpEF)
St. George's University Of London, 
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Christian Hengstenberg practices in London, United Kingdom. Mr. Hengstenberg is rated as a Distinguished expert by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Cardiac Amyloidosis, Tricuspid Regurgitation, Heart Failure, Transcatheter Aortic Valve Replacement (TAVR), and Aortic Valve Replacement.

His clinical research consists of co-authoring 411 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 20 articles in the study of Heart Failure with Preserved Ejection Fraction (HFpEF).

Gender
Male

Locations

St. George's University Of London, London, ENG, United Kingdom
Other Locations
Franz Josef Strauss Allee 11, Allee, SH 93053, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Transcatheter Repair of Mitral Regurgitation With Edwards PASCAL Transcatheter Valve Repair System: A European Prospective, Multicenter Post Market Clinical Follow-Up (PMCF)
Transcatheter Repair of Mitral Regurgitation With Edwards PASCAL Transcatheter Valve Repair System: A European Prospective, Multicenter Post Market Clinical Follow-Up (PMCF)
Enrollment Status: Recruiting
Publish Date: June 26, 2025
Intervention Type: Device
Safety and Efficacy Comparison Of Two TAVI Systems in a Prospective Randomized Evaluation II: A Randomized, Controlled, Non-inferiority Trial Evaluating Safety and Clinical Efficacy of the Symetis ACURATE Neo Compared to the Medtronic Evolut R Bioprosthesis in Transfemoral Transcatheter Aortic Valve Implantation
Safety and Efficacy Comparison Of Two TAVI Systems in a Prospective Randomized Evaluation II: A Randomized, Controlled, Non-inferiority Trial Evaluating Safety and Clinical Efficacy of the Symetis ACURATE Neo Compared to the Medtronic Evolut R Bioprosthesis in Transfemoral Transcatheter Aortic Valve Implantation
Enrollment Status: Completed
Publish Date: June 11, 2020
Intervention Type: Device
View 1 Less Clinical Trial

411 Total Publications

Mitochondrial ROS drive foam cell formation via STAT5 signaling in atherosclerosis.
Mitochondrial ROS drive foam cell formation via STAT5 signaling in atherosclerosis.
Journal: Science advances
Published: August 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hengstenberg's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 8 Advanced Conditions
View All 49 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile